ACM
GMAB icon

Arlington Capital Management’s Genmab GMAB Stock Holding History

Arlington Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,489
Closed -$1.39M – 89
2023
Q2 		$1.39M Buy
36,489
+898
+3% +$35.8K 1.2% 24
2023
Q1 		$1.34M Buy
35,591
+9,476
+36% +$364K 1.26% 26
2022
Q4 		$1.11M Buy
+26,115
New +$1.08M 1.24% 27

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Arlington Capital Management's GMAB Position: Q3 2023 in Review

Arlington Capital Management sold out of Genmab (GMAB) in Q3 2023, closing a stake of 36,489 shares — an estimated $1.39M sold.

Arlington Capital Management first reported a position in GMAB in Q4 2022 and held it in 3 quarters. The position peaked at $1.39M in Q2 2023. 233 funds tracked by Wall St. Rank hold GMAB as of Q3 2023.

  • Arlington Capital Management reported no remaining Genmab position as of Q3 2023 after selling out during the quarter.
  • Arlington Capital Management sold 36,489 Genmab shares in Q3 2023, an estimated $1.39M.
  • Arlington Capital Management first reported a position in Genmab in Q4 2022 and held it in 3 quarters.
  • Arlington Capital Management's Genmab position peaked at $1.39M in Q2 2023.
  • 233 funds tracked by Wall St. Rank held Genmab as of Q3 2023.

Based on Arlington Capital Management's 13F filing for Q3 2023, filed 25 Oct 2023.